{"Abbreviation":"","Aliases":["12-Methoxyibogamine","Endabuse","(-)-Ibogaine","(5β)-12-methoxyibogamine","(18R)-12-methoxyibogamine","7-Ethyl-6,6β,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido(1',2':1,2)azepino(5,4-b)indole","12 Methoxyibogamine","6,9-Methano-5H-pyrido(1',2':1,2)azepino(4,5-b)indole, ibogamine deriv.","6,9-Methano-5H-pyrido[1',2':1,2]azepino[4,5-b]indole, ibogamine deriv.","(1R,15R,17S,18S)-17-ethyl-7-methoxy-3,13-diazapentacyclo(13.3.1.02,10.04,9.013,18)nonadeca-2(10),4(9),5,7-tetraene"],"Biological Half-Life":"To investigate the pharmacokinetic properties of ibogaine, a putatively anti-addictive alkaloid, levels of this drug were quantified in plasma and tissues for up to 3 hr following i.v. infusion in rats. Immediately following a 31-35 min infusion (20 mg/kg). ... The plasma time course in 5 of 7 animals demonstrated an excellent fit to a two-compartment pharmacokinetic model, with alpha and beta half-lives of 7.3 min and 3.3 hr, respectively. ...","CAS":"83-74-9","ChEBI":"CHEBI:5852","ChEMBL":"CHEMBL1215855","ChemicalClasses":["tryptamine"],"Chirality":"absolute","Classes":["Psychedelic"],"DEA no":7260,"DrugClasses":["hallucinogens"],"EINECS":"201-498-4","EliminationHalfLife":"","Erowid Experience Reports":[{"Author":"Morninggloryseed","Id":"100221","Title":"Defragmentation And Factory Restore1"},{"Author":"Lora_","Id":"103610","Title":"My Beautiful Trip"},{"Author":"Bjorn C.","Id":"103981","Title":"Spectacular, Sacramental Meeting"},{"Author":"Aidenn","Id":"104306","Title":"The Cure for Opiate Addiction"},{"Author":"Marie","Id":"104421","Title":"My Most Beautiful Experience"},{"Author":"slavior","Id":"107328","Title":"Not a Miracle Cure Semi Scam..."},{"Author":"Josh K.","Id":"110725","Title":"Ancestral Recall"},{"Author":"Joan Clark","Id":"113307","Title":"I Was Surprised at the Strength"},{"Author":"Stray","Id":"113705","Title":"Anti Addiction Properties"},{"Author":"Caspar","Id":"16466","Title":"In the Arms of the Uncontrolled"},{"Author":"Linda Kay Scott","Id":"1948","Title":"A Gift of Freedom"},{"Author":"Daniel Pinchbeck","Id":"20492","Title":"Primordial Wisdom Teacher"},{"Author":"Sugoi","Id":"26381","Title":"Scratching the Surface"},{"Author":"C.S.","Id":"39692","Title":"Powerful But Gentle"},{"Author":"Matthew","Id":"41522","Title":"Breaking Open the Head"},{"Author":"Zonkermon","Id":"42703","Title":"Beautiful but not Easy"},{"Author":"allotrope","Id":"58716","Title":"Found the 'On' Switch in My Soul"},{"Author":"Psychenaut","Id":"63024","Title":"Rebirth"},{"Author":"Lightofiboga","Id":"63089","Title":"Saved from Addiction"},{"Author":"tobala","Id":"68933","Title":"Welcome Back to My Life"},{"Author":"cricket","Id":"76606","Title":"Bwiti Spoke in Soft Measure"},{"Author":"D.L., NV","Id":"79833","Title":"A Guided Ibogaine Experience"},{"Author":"KBF","Id":"76892","Title":"A Psycho-Spiritual Experience"},{"Author":"fox and rabbit","Id":"83861","Title":"Solidity in the Absolute"},{"Author":"johnny k","Id":"83551","Title":"Low Dose Experiment"},{"Author":"Survivor","Id":"86662","Title":"Clean from Opium Tea"}],"European Community (EC) Number":"201-498-4","FullSalts":["Ibogaine hydrochloride"],"HeavyAtomCount":23,"Human Drugs":"Pharmaceuticals","IUPACName":"(1R,15R,17S,18S)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene","InChI":"InChI=1S/C20H26N2O/c1-3-13-8-12-9-17-19-15(6-7-22(11-12)20(13)17)16-10-14(23-2)4-5-18(16)21-19/h4-5,10,12-13,17,20-21H,3,6-9,11H2,1-2H3/t12-,13+,17+,20+/m1/s1","InChIKey":"HSIBGVUMFOSJPD-CFDPKNGZSA-N","MeSH Pharmacological Classification":"Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations, and other alterations of mood and thinking. Despite the name, the feature that distinguishes these agents from other classes of drugs is their capacity to induce states of altered perception, thought, and feeling that are not experienced otherwise. (See all compounds classified as Hallucinogens.)","Melting Point":"148 °C","MolecularFormula":"C\u003csub\u003e20\u003c/sub\u003eH\u003csub\u003e26\u003c/sub\u003eN\u003csub\u003e2\u003c/sub\u003eO","MolecularWeight":"310.4 g/mol","Opticalactivity":"UNSPECIFIED","PrevSalts":["hydrochloride"],"PubChemId":197060,"Record Description":["Ibogaine is an organic heteropentacyclic compound that is ibogamine in which the indole hydrogen para to the indole nitrogen has been replaced by a methoxy group. It has a role as a plant metabolite, an inhibitor, a hallucinogen and a oneirogen. It is a monoterpenoid indole alkaloid, an organic heteropentacyclic compound and an aromatic ether. It is functionally related to an ibogamine. It is a conjugate base of an ibogaine(1+).","Ibogaine is a DEA Schedule I controlled substance. Substances in the DEA Schedule I have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse. It is a Hallucinogenic substances substance.","Ibogaine has been reported in Trachelospermum jasminoides, Tabernanthe iboga, and other organisms with data available.","One of several indole alkaloids extracted from Tabernanthe iboga, Baill. It has a complex pharmacological profile, and interacts with multiple systems of neurotransmission. Ibogaine has psychoactive properties and appears to modulate tolerance to opiates.","Ibogaine is an organic heteropentacyclic compound that is ibogamine in which the indole hydrogen para to the indole nitrogen has been replaced by a methoxy group. It has a role as a plant metabolite, an inhibitor, a hallucinogen and a oneirogen. It is a monoterpenoid indole alkaloid, an organic heteropentacyclic compound and an aromatic ether. It is functionally related to an ibogamine. It is a conjugate base of an ibogaine(1+).","Wikipedia|TiHKAL|Tryptamines"],"RefCount":4,"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Ibogaine","Name":"Ibogaine","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q409455","Name":"Ibogaine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/197060","Name":"Ibogaine","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1215855","Name":"Ibogaine","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5852","Name":"Ibogaine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=83-74-9","Name":"Ibogaine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/3S814I130U","Name":"Ibogaine","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID20894069","Name":"Ibogaine","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 197060, Ibogaine. Accessed June 26, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/197060\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/197060\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Ibogaine. UNII: 3S814I130U. Global Substance Registration System. Accessed June 26, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/3S814I130U\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/3S814I130U\u003c/a\u003e","Notice - Prescription Drug List (PDL): Multiple additions. Government of Canada, Health. May 12, 2017. Accessed June 26, 2025. \u003ca href=http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl-ldo-noa-ad-2017-05-16-eng.php\u003ehttp://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl-ldo-noa-ad-2017-05-16-eng.php\u003c/a\u003e"],"SMILES":"CC[C@H]1C[C@@H]2C[C@@H]3[C@H]1N(C2)CCC4=C3NC5=C4C=C(C=C5)OC","Salts":["hydrochloride"],"SaltsAcidCount":[1],"SaltsAmineCount":[1],"SaltsUNII":["MRI8GKD98X"],"Scheduling":[{"gov":"Australia","ref":[],"schedule":"S4 substance"},{"gov":"Canada","ref":["3"],"schedule":"Prescription only substance"},{"gov":"New Zealand","ref":[],"schedule":"Prescription only substance"},{"gov":"United Kingdom","ref":[],"schedule":"PSA substance"},{"gov":"United Nations","ref":[],"schedule":"Unscheduled substance"},{"act":"Controlled Substances Act (CSA)","gov":"United States","ref":[],"schedule":"Schedule I"}],"Solubility":"Soluble in chloroform","Stability/Shelf Life":"Stable under recommended storage conditions. /Ibogaine hydrochloride/","StoreUNII":["3S814I130U"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="69.407mm" version="1.2" viewBox="0 0 128.061 69.407" width="128.061mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#000000" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="70.0" stroke="none" width="129.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="120.602" x2="108.542" y1="68.356" y2="59.039"/>
                  
            <g class="bond" id="mol1bnd2">
                        
                <line x1="110.858" x2="110.304" y1="44.15" y2="43.722"/>
                        
                <line x1="110.764" x2="109.815" y1="46.461" y2="45.727"/>
                        
                <line x1="110.671" x2="109.325" y1="48.771" y2="47.731"/>
                        
                <line x1="110.577" x2="108.836" y1="51.081" y2="49.736"/>
                        
                <line x1="110.484" x2="108.347" y1="53.392" y2="51.741"/>
                        
                <line x1="110.391" x2="107.858" y1="55.702" y2="53.746"/>
                        
                <line x1="110.297" x2="107.369" y1="58.013" y2="55.75"/>
                        
                <line x1="110.204" x2="106.88" y1="60.323" y2="57.755"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd3" x1="110.581" x2="124.68" y1="43.936" y2="38.152"/>
                  
            <g class="bond" id="mol1bnd4">
                        
                <line x1="126.397" x2="127.044" y1="23.183" y2="22.917"/>
                        
                <line x1="125.787" x2="126.974" y1="25.81" y2="25.323"/>
                        
                <line x1="125.177" x2="126.904" y1="28.438" y2="27.73"/>
                        
                <line x1="124.567" x2="126.833" y1="31.066" y2="30.136"/>
                        
                <line x1="123.957" x2="126.763" y1="33.694" y2="32.542"/>
                        
                <line x1="123.346" x2="126.693" y1="36.321" y2="34.948"/>
                        
                <line x1="122.736" x2="126.623" y1="38.949" y2="37.355"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd5" x1="126.72" x2="85.663" y1="23.05" y2="57.677"/>
                  
            <path class="bond" d="M85.783 42.433l-.7 .011l-1.702 17.615l2.289 -1.93l1.896 -1.599z" id="mol1bnd6" stroke="none"/>
                  
            <line class="bond" id="mol1bnd7" x1="85.433" x2="98.52" y1="42.439" y2="34.62"/>
                  
            <path class="bond" d="M110.571 44.277c-.074 .0 -.148 -.021 -.204 -.064l-3.781 -2.921l.545 -.463v.0l3.664 2.83c.138 .107 .17 .353 .063 .491c-.064 .083 -.177 .127 -.287 .127zM105.027 40.088l-6.721 -5.191c-.017 .016 -.032 .024 -.045 .024c-.099 -.0 -.112 -.394 -.018 -.515c.064 -.083 .177 -.127 .287 -.127c.075 -.0 .148 .02 .204 .064l6.839 5.282v.0l-.546 .463z" id="mol1bnd8" stroke="none"/>
                  
            <path class="bond" d="M98.173 34.573l.694 .093l2.817 -11.095l-1.641 -.222l-1.64 -.222z" id="mol1bnd9" stroke="none"/>
                  
            <line class="bond" id="mol1bnd10" x1="103.798" x2="114.663" y1="18.185" y2="13.731"/>
                  
            <line class="bond" id="mol1bnd11" x1="126.72" x2="114.663" y1="23.05" y2="13.731"/>
                  
            <line class="bond" id="mol1bnd12" x1="97.653" x2="90.019" y1="16.473" y2="8.499"/>
                  
            <line class="bond" id="mol1bnd13" x1="90.019" x2="74.837" y1="8.499" y2="9.881"/>
                  
            <line class="bond" id="mol1bnd14" x1="74.837" x2="66.463" y1="9.881" y2="22.616"/>
                  
            <g class="bond" id="mol1bnd15">
                        
                <line x1="71.168" x2="66.463" y1="37.071" y2="22.616"/>
                        
                <line x1="68.3" x2="64.691" y1="36.139" y2="25.049"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd16" x1="85.433" x2="71.168" y1="42.439" y2="37.071"/>
                  
            <line class="bond" id="mol1bnd17" x1="71.168" x2="61.939" y1="37.071" y2="43.769"/>
                  
            <line class="bond" id="mol1bnd18" x1="55.79" x2="46.492" y1="43.779" y2="37.065"/>
                  
            <g class="bond" id="mol1bnd19">
                        
                <line x1="46.492" x2="51.201" y1="37.065" y2="22.571"/>
                        
                <line x1="44.608" x2="48.447" y1="34.972" y2="23.157"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd20" x1="66.463" x2="51.201" y1="22.616" y2="22.571"/>
                  
            <line class="bond" id="mol1bnd21" x1="51.201" x2="40.995" y1="22.571" y2="11.243"/>
                  
            <g class="bond" id="mol1bnd22">
                        
                <line x1="40.995" x2="26.078" y1="11.243" y2="14.408"/>
                        
                <line x1="40.125" x2="27.962" y1="13.92" y2="16.501"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd23" x1="26.078" x2="21.369" y1="14.408" y2="28.902"/>
                  
            <g class="bond" id="mol1bnd24">
                        
                <line x1="21.369" x2="31.576" y1="28.902" y2="40.231"/>
                        
                <line x1="24.123" x2="32.446" y1="28.317" y2="37.554"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd25" x1="46.492" x2="31.576" y1="37.065" y2="40.231"/>
                  
            <line class="bond" id="mol1bnd26" x1="26.078" x2="18.537" y1="14.408" y2="6.03"/>
                  
            <line class="bond" id="mol1bnd27" x1="12.254" x2=".975" y1="3.852" y2="6.247"/>
                  
            <path class="atom" d="M102.503 21.961h-.721l-2.619 -4.066h-.03q.012 .239 .03 .596q.024 .357 .024 .732v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" fill="#3050F8" id="mol1atm9" stroke="none"/>
                  
            <g class="atom" id="mol1atm15">
                        
                <path d="M60.806 48.45h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.023 .357 .023 .732v2.739h-.565v-4.9h.714l2.608 4.054h.029q-.006 -.107 -.017 -.327q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.483v-2.768h.577v4.9z" fill="#3050F8" stroke="none"/>
                        
                <path d="M60.669 53.911h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619v4.9z" fill="#3050F8" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M18.142 3.078q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.757 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.251 -.566 .757 -.881q.506 -.316 1.273 -.316q.733 .0 1.233 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM14.278 3.078q.0 .923 .387 1.459q.393 .53 1.221 .53q.839 -.0 1.22 -.53q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .523 -.393 1.452z" fill="#FF0D0D" id="mol1atm22" stroke="none"/>
                
            <line class="hi" id="mol1bnd10" stroke="#3050F8" x1="103.798" x2="109.2305" y1="18.185" y2="15.957999999999998"/>
            <line class="hi" id="mol1bnd12" stroke="#3050F8" x1="97.653" x2="93.83600000000001" y1="16.473" y2="12.486"/>
            <line class="hi" id="mol1bnd17" stroke="#3050F8" x1="61.939" x2="66.5535" y1="43.769" y2="40.42"/>
            <line class="hi" id="mol1bnd18" stroke="#3050F8" x1="55.79" x2="51.141" y1="43.779" y2="40.422"/>
            <line class="hi" id="mol1bnd26" stroke="#FF0D0D" x1="18.537" x2="22.307499999999997" y1="6.029999999999999" y2="10.219"/>
            <line class="hi" id="mol1bnd27" stroke="#FF0D0D" x1="12.254" x2="6.6145" y1="3.852" y2="5.0495"/>
        </g>
          
    </g>
    
</svg>
","Subjective Effects":null,"Therapeutic Uses":"/EXPL THER/ Ibogaine is a hallucinogenic indole alkaloid extracted from the West African shrub tabernanthe iboga (Apocynaceae). It has been investigated as an aid to withdrawal from drug addiction.","Title":"Ibogaine","UNII":"3S814I130U","Wikidata":"Q409455","Wikipedia":"Ibogaine","XLogP":3.9}